CEO Jan Møller Mikkelsen said Ascendis Pharma A/S is "still analyzing a lot of the data" from its phase III trial with its Transcon human growth hormone (hGH), a weekly therapy that beat daily growth hormone in the experiment called Height, but researchers are able to affirm that the better-than-expected outcome was "driven by the molecule itself, not by a difference in adherence between the two arms" of the study.